Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.60 |
| ▸ | BACE1 | P56817 | 2/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.59 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148958 | 0.94 | ACHE (0.60) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL4485265 | 0.91 | CNR2 (0.60) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL22755777 | 0.89 | MEN1 (0.68) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL6023725 | 0.89 | MEN1 (0.68) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL3598146 | 0.89 | MEN1 (0.68) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL6701595 | 0.86 | KMT2A (0.65) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL19493714 | 0.84 | SLC18A3 (0.70) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL8435485 | 0.84 | SLC18A3 (0.79) | SLC18A3SIGMAR1 | |
| SCHEMBL4697182 | 0.83 | CNR2 (0.78) | MEN1KMT2ABCHEACHEBACE1 | |
| SCHEMBL29832299 | 0.81 | TRPV6 (0.64) | MEN1KMT2ASLC18A3CCR5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | MEN1 4355/4885KMT2A 1738/4885BCHE 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.